NASDAQ:RDNT - RadNet Stock Price, Forecast & News

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

RadNet Inc. (NASDAQ:RDNT) posted its earnings results on Tuesday, November, 12th. The medical research company reported $0.06 earnings per share for the quarter, missing analysts' consensus estimates of $0.11 by $0.05. The medical research company earned $292.70 million during the quarter, compared to the consensus estimate of $283.39 million. RadNet had a net margin of 3.02% and a return on equity of 16.52%. The firm's revenue was up 20.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.10 EPS. View RadNet's Earnings History.

RadNet is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for RadNet.

RadNet will be holding an earnings conference call on Thursday, March 12th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

RadNet issued an update on its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $$1.1-1.15 billion, compared to the consensus revenue estimate of $$1.13 billion.

2 equities research analysts have issued 12-month price objectives for RadNet's shares. Their forecasts range from $17.50 to $23.00. On average, they expect RadNet's stock price to reach $20.25 in the next twelve months. This suggests that the stock has a possible downside of 11.7%. View Analyst Price Targets for RadNet.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for RadNet.

News articles about RDNT stock have trended negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. RadNet earned a coverage optimism score of -2.9 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for RadNet.

RadNet saw a decline in short interest in January. As of January 31st, there was short interest totalling 1,160,000 shares, a decline of 18.3% from the January 15th total of 1,420,000 shares. Based on an average daily trading volume, of 513,300 shares, the days-to-cover ratio is presently 2.3 days. Currently, 2.8% of the company's stock are short sold. View RadNet's Current Options Chain.

Some companies that are related to RadNet include ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), Veracyte (VCYT), CareDx (CDNA), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Personalis (PSNL), Centogene (CNTG), DermTech (DMTK), Anpac Bio-Medical Science (ANPC), Enzo Biochem (ENZ), Celcuity (CELC), Psychemedics (PMD) and Miragen Therapeutics (MGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other RadNet investors own include Advanced Micro Devices (AMD), Rigel Pharmaceuticals (RIGL), AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), AT&T (T), UnitedHealth Group (UNH), Athersys (ATHX), Corcept Therapeutics (CORT), Catalyst Pharmaceuticals (CPRX) and Inovio Pharmaceuticals (INO).

RadNet's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (6.62%), Renaissance Technologies LLC (3.51%), State Street Corp (2.42%), Beck Mack & Oliver LLC (2.11%), Global Alpha Capital Management Ltd. (2.04%) and Dalton Greiner Hartman Maher & Co. (1.68%). Company insiders that own RadNet stock include David L Swartz, Jeffrey L Linden, John V Crues, Mark Stolper, Marvin S Cadwell, Michael L Md Sherman, Michael N Murdock and Norman R Hames. View Institutional Ownership Trends for RadNet.

RDNT stock was sold by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Global Alpha Capital Management Ltd., Royce & Associates LP, Cheyne Capital Management UK LLP, Russell Investments Group Ltd., Cadence Capital Management LLC, Alliancebernstein L.P. and Assenagon Asset Management S.A.. Company insiders that have sold RadNet company stock in the last year include David L Swartz, John V Crues, Mark Stolper, Michael L Md Sherman, Michael N Murdock and Norman R Hames. View Insider Buying and Selling for RadNet.

RDNT stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Principal Financial Group Inc., State Street Corp, Bank of New York Mellon Corp, Punch & Associates Investment Management Inc., Candriam Luxembourg S.C.A., Public Sector Pension Investment Board and Citigroup Inc.. View Insider Buying and Selling for RadNet.

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RDNT stock can currently be purchased for approximately $22.94.

RadNet has a market capitalization of $1.15 billion and generates $975.15 million in revenue each year. The medical research company earns $32.24 million in net income (profit) each year or $0.66 on an earnings per share basis. RadNet employs 7,869 workers across the globe.View Additional Information About RadNet.

The official website for RadNet is http://www.radnet.com/.

RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at 310-478-7808 or via email at [email protected]